According to the CDC, how often should COVID‑19 vaccines be administered for individuals of all ages, including recommendations for yearly boosters, immunocompromised patients, and pregnant people?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

CDC COVID-19 Vaccine Recommendations: Annual Dosing for All Ages ≥6 Months

Yes, the CDC now recommends annual COVID-19 vaccination for all persons aged ≥6 months, effectively establishing a yearly vaccination schedule similar to influenza vaccination. 1

Universal Annual Vaccination Recommendation

The Advisory Committee on Immunization Practices (ACIP) voted in June 2024 to recommend that everyone aged ≥6 months receive the updated 2024-2025 COVID-19 vaccine annually 1. This represents a shift to a predictable yearly vaccination schedule for the general population, moving away from the previous multi-dose primary series approach for most individuals.

For Immunocompetent Persons (Not Moderately/Severely Immunocompromised)

Standard dosing is straightforward:

  • Ages 5-11 years: 1 dose of 2024-2025 mRNA vaccine (Moderna or Pfizer-BioNTech) 1
  • Ages ≥12 years: 1 dose of 2024-2025 vaccine (Moderna, Pfizer-BioNTech, or Novavax) 1
  • Timing: Administer ≥8 weeks after the last COVID-19 vaccine dose 1

Exception for young children (6 months-4 years): This age group requires a multi-dose initial series when first vaccinated:

  • Moderna: 2 doses (4-8 weeks apart)
  • Pfizer-BioNTech: 3 doses (3-8 weeks between doses 1-2, then ≥8 weeks between doses 2-3) 1

Once the initial series is complete, these children will transition to annual single-dose boosters in subsequent years.

For Immunocompromised Persons

Immunocompromised individuals require more intensive vaccination:

The recommendations differ substantially for those with moderate to severe immunocompromise, recognizing their increased risk for severe COVID-19 and potentially diminished vaccine response 1.

Initial vaccination (if unvaccinated):

  • Ages 6 months-11 years: 3-dose series of 2024-2025 mRNA vaccine (same manufacturer) 1
  • Ages ≥12 years: Either 3 doses of 2024-2025 mRNA vaccine (same manufacturer) OR 2 doses of Novavax 1

Additional dosing flexibility: After completing the initial series and receiving at least 1 dose of 2024-2025 vaccine, immunocompromised persons may receive 1 additional dose at least 2 months after the last dose 1. Further additional doses can be administered based on clinical judgment, personal preference, and individual circumstances, with each dose separated by at least 2 months 1.

This effectively allows for more frequent than annual vaccination in immunocompromised populations when clinically indicated.

Rationale for Annual Vaccination

The shift to annual vaccination reflects several key factors:

  1. Persistent disease burden: COVID-19 continues to cause significant morbidity and mortality, with 67% of hospitalizations occurring in persons aged ≥65 years during October 2023-January 2024 2

  2. Waning immunity: Vaccine-conferred protection decreases over time, necessitating periodic boosting 2

  3. Viral evolution: SARS-CoV-2 continues to evolve, requiring updated vaccine formulations (current vaccines target JN.1 and KP.2 lineages) 1

  4. Simplified public health messaging: An annual schedule aligns with influenza vaccination patterns, making it easier for the public to understand and comply 3

Special Considerations

Pregnant women: While the guidelines don't specifically call out pregnancy as requiring different dosing frequency, pregnant individuals should follow the standard recommendations for their age and immunocompromise status. The general recommendation applies universally to all persons ≥6 months 1.

Older adults (≥65 years): In 2024, ACIP specifically recommended an additional dose of the 2023-2024 vaccine for persons ≥65 years due to their elevated risk for severe outcomes 2. This demonstrates that older adults may benefit from more frequent dosing during periods of high transmission, though the baseline recommendation remains annual.

Timing optimization: For populations receiving two doses (such as immunocompromised individuals or young children in their initial series), optimal spacing is 5 months between doses to maximize protection 3.

Clinical Pitfalls to Avoid

  • Don't assume all patients need only one dose annually: Immunocompromised patients require individualized assessment and may need additional doses beyond the annual recommendation
  • Don't forget the 8-week minimum interval: Doses given too close together may not provide optimal immune response 1
  • Don't overlook young children's multi-dose requirements: Children 6 months-4 years need their complete initial series, not just a single dose 1
  • Don't use outdated vaccine formulations: Only 2024-2025 vaccines should be administered; previous formulations are no longer recommended 1

The evidence strongly supports annual COVID-19 vaccination as the new standard of care, with enhanced schedules for vulnerable populations including the immunocompromised and very young children.

References

Related Questions

Should a 79‑year‑old individual receive an annual COVID‑19 vaccine?
Is a COVID-19 (Coronavirus Disease 2019) vaccination every 6 months necessary?
How should I manage a 75-year-old man with a 4‑day history of generalized body aches and weakness, negative for streptococcal infection, influenza, and COVID‑19, no upper respiratory infection, and who is taking atorvastatin, allopurinol, lisinopril, and meloxicam?
What diseases, other than COVID-19, increase transmural dispersion of repolarization?
What is the appropriate workup and management for a patient who has lost 60 lb (≈27 kg) over the past 18 months after COVID‑19 infection and now presents with bradycardia and resting oxygen saturation of 88‑92 %?
What is the appropriate dosing and duration of terbinafine (1% cream or oral) for a healthy adult with limited tinea corporis?
Can mirtazapine cause tremors, and what is the recommended management?
Can progestin-only oral contraceptives be used in patients with migraine with aura?
What are the indications for coronary artery calcium (CAC) scanning?
Which hormones are regulated by the pituitary gland?
What is the antimalarial of choice for a patient with a prolonged QT interval?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.